Marketing
-
Novartis gene therapy approved, but will come at cost of more than $2 million
Zolgensma is designed to be a cure for spinal muscular atrophy, but its steep price will pose difficulties for a system designed for chronic therapy rather than one-time treatments.
By Ned Pagliarulo • UPDATED: May 24, 2019 at 2:03 p.m. -
ICER sees current DMD therapies as too pricey, but notes data limitations
Though evidence supporting Sarepta's eteplirsen and golodirsen and PTC's deflazacort "remains sparse," ICER expects all three drugs wouldn't hit certain cost-effectiveness thresholds.
By Jacob Bell • May 23, 2019 -
Private payers cover more than 40% of drug costs
Patients pay 14% of overall retail drug spend in the U.S. in the form of out-of-pocket costs, according to a new analysis from the Kaiser Family Foundation.
By Rebecca Pifer • May 21, 2019 -
ICER seeks to make drug price research more accessible
Pharmas and payers use ICER's work to inform their approach on pricing and coverage, making the group a key voice in the debate over drug value.
By Ned Pagliarulo • May 20, 2019 -
The NASH dash runs into some early hurdles
In a trio of articles, BioPharma Dive explored the key problems the NASH field faces and what's being done to solve them.
By Jacob Bell • May 17, 2019 -
Deep DiveNo one knows the size of the NASH market
Industry is still using a broad estimate for the NASH population, which has led to very different views on the size of the potential market opportunity.
By Jacob Bell • May 16, 2019 -
Deep DiveOn the path to patients, NASH drugs may hit a payer roadblock
Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.
By Jacob Bell • May 15, 2019 -
Deep DiveWill a big needle burst the NASH bubble?
With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market.
By Jacob Bell • May 14, 2019 -
Gilead donates Truvada for PrEP to CDC, with mixed reactions
While the donation will make the preventive treatment available to uninsured Americans, it doesn't lower the cost for others.
By Andrew Dunn • May 10, 2019 -
Nearing gene therapy launch, Bluebird cautions a slower start
Zynteglo, Bluebird's experimental therapy for beta-thalassemia, could soon be cleared in Europe. Reworking payment models to adjust will take time.
By Ned Pagliarulo • May 09, 2019 -
Drugmakers will soon be required to disclose prices in TV ads
Forcing pharma's hand, the Trump administration finalized a proposal requiring list prices in DTC advertising, inviting a possible legal challenge from industry.
By Ned Pagliarulo • May 08, 2019 -
Catalyst dives as FDA approves rival's rare disease drug
Jacobus Pharmaceutical's Ruzurgi is cleared for a different age range than Catalyst's Firdapse, yet investors appear concerned about off-label use eroding the latter's business.
By Jacob Bell • May 07, 2019 -
J&J touts YouTube successes after growing spend on the platform 250%
While drugmaker marketing for pharmaceuticals still relies heavily on TV, J&J has found success with digital advertising for its consumer brands.
By Peter Adams • May 03, 2019 -
Alnylam posts strong Onpattro sales as competition heats up
Onpattro's performance in the first quarter beat expectations. But can Alnylam sustain that momentum if Pfizer wins approval for its would-be rival tafamidis?
By Ned Pagliarulo • May 02, 2019 -
Pfizer prospects for tafamidis market
The rare disease tafamidis treats is underdiagnosed, Pfizer says, so increasing awareness will be essential. Payers, meanwhile, may seek outcomes-based contracts.
By Jonathan Gardner • April 30, 2019 -
At gene therapy meeting, insurance execs grapple with expected cost
As more gene therapies move closer to market, questions around pricing and reimbursement have taken on greater urgency for regulators, payers and drugmakers.
By Ned Pagliarulo • April 30, 2019 -
Praluent scores heart label, matching Amgen's rival Repatha
The cholesterol drug from Sanofi and Regeneron is now approved for prevention of cardiovascular events like heart attack or stroke.
By Ned Pagliarulo • April 29, 2019 -
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal
Louisiana inked a similar agreement last month with a Gilead subsidiary, pioneering a model that aims to boost access while containing drug costs.
By Andrew Dunn • UPDATED: April 26, 2019 at 4:40 p.m. -
Praluent's lower list price isn't yielding better sales yet
Though the Sanofi-Regeneron cholesterol drug took a 60% list price cut in March, stateside sales were down 27% due to "significantly increased rebates."
By Jacob Bell • April 26, 2019 -
Novartis chief defends cell, gene therapy push
CEO Vas Narasimhan has bet heavily on complex medicines, but the pharma's first quarter earnings show that plan is a work in progress.
By Ned Pagliarulo • April 24, 2019 -
'Meet PillPack': Amazon rolls out Rx delivery direct marketing
The marketing provides a peek behind the curtain of the famously secretive e-commerce giant, which has edged into healthcare in recent years.
By Rebecca Pifer • April 24, 2019 -
Competition and doughnut hole discount takes toll on Xarelto sales
Johnson & Johnson, which sells Xarelto in the U.S., saw first quarter sales for the anticoagulant decline 6% despite pricing and prescription increases.
By Jonathan Gardner • April 23, 2019 -
SponsoredPatient centricity: Buzzword or rebirth of the CRO industry?
Now that patient centricity is popularizing, CROs are scrambling to look good for sponsors, investors, and patients.
By Natania Barron, Director Global Marketing • April 23, 2019 -
Sandoz takes United Therapeutics to court for 'anticompetitive' behavior
The generics arm of Novartis recently launched a copycat version of United's top-seller Remodulin, but says a "secret arrangement" is preventing patients from getting it.
By Jacob Bell • April 18, 2019 -
$300M loan boosts launch of TherapeuticsMD hot flash pill
Bijuva marketing is beginning thanks to an immediate $200 million cash infusion, with the remainder released on regulatory and sales milestones.
By Jonathan Gardner • April 18, 2019
